Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.
As of March 26, 2021, the Company had not commenced core operations. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.
Our biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability.
We aim to focus on mechanism-based immune treatments for the treatment of these disorders. Our secondary operations are focused on establishing anti-depression clinics across the United Kingdom and providing business support services to similar entities in the United States and using psychiatric assessment combined with physician/medical providers to administer intravenous infusions of ketamine.
As of the date of this prospectus, ketamine is gaining grounds as a promising treatment for some cases of major depression.
|IPO Date||Sep 15, 2021|
|CEO||Dr. Tiago Reis Marques|
1111 Lincoln Road, Suite 500
Miami Beach, FL 33139
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Tiago Reis Marques||Chief Executive Officer and Director|
|Prof. Lawrence Steinman BA, M.D.||Executive Chairman and Co-Founder|
|Stanley M. Gloss||Chief Financial Officer|
|Dr. Yassine Bendiabdallah||Chief Operating Officer, Head of UK Clinics and Director|